Comorbidity of migraine and magnesium deficiency: Limitations of diagnosis and treatment

Migraine is a common chronic neurological disease that involves different forms of attacks and is characterized by recurring episodes of intense headache. Migraine is a top ten disabling neurological disease and remains the second-ranked cause of disability in adults among noncommunicable diseases. Magnesium deficiency is also a common pathological condition caused by various reasons including insufficient levels of magnesium intake from food sources or increased losses through the gastrointestinal or renal systems. We finally have a sufficient number of studies that demonstrate the frequent comorbidity between migraine and magnesium deficiency, however measured plasma magnesium levels do not always objectively reflect the presence or absence of total body magnesium deficiency, as only 10% of the total body magnisium is extracellular. Other clinical manifestations of hypomagnesemia should also be considered. Magnesium deficiency in patients with migraine has been proven to lead to aggravation of the disease. The reason for this is an effect of magnesium deficiency on the main mechanisms of migraine pathogenesis, including impaired energy supply, cortical spreading depression, neurogenic inflammation and central sensitization. Numerous studies have revealed the potential effectiveness of adding magnesium supplements to the combination therapy of migraine. The article discusses the relationship between magnesium deficiency and migraine, the role of magnesium in the migraine pathogenesis and the feasibility of use of magnesium supplements to prevent and treat migraine.

1. Charles A. The pathophysiology of migraine: implications for clinical management. Lancet Neurol. 2018;17(2):174–182. https://doi.org/10.1016/S14744422(17)304350.

2. Rasmussen BK, Jensen R, Schroll M, Olesen J. Epidemiology of headache in a general population – a prevalence study. J Clin Epidemiol. 1991;44(11):1147–1157. https://doi.org/10.1016/08954356(91)901472.

3. Ashina M. Migraine. N Engl J Med. 2020;383(19):1866–1876. https://doi.org/10.1056/NEJMra1915327.

4. Cuciureanu DI, Bistriceanu CE, Vulpoi GA, Cuciureanu T, Antochi F, Roceanu AM. Migraine Comorbidities. Life. 2024;14(1):74. https://doi.org/10.3390/life14010074.

5. Ayuk J, Gittoes NJ. Contemporary view of the clinical relevance of magnesium homeostasis. Ann Clin Biochem. 2014;51(Pt 2):179–188. https://doi.org/10.1177/0004563213517628.

6. Shilov AM. Magnesium deficiency and cardiovascular continuum. Lechebnoe Delo. 2013;(4):73–82. (In Russ.) Available at: https://www.elibrary.ru/rxdumj.

7. Shilov AM, Mel’nik MV, Osiya AO, Sviridova AYu, Gryaznov DA. The role of magnesium deficiency in the pathogenesis of metabolic syndrome. RMJ. 2008;16(21):1439–1444. (In Russ.) Available at: https://www.rmj.ru/articles/kardiologiya/Roly_deficita_magniya_v_patogeneze_metabolicheskogo__sindroma.

8. Gromova OA, Kalacheva AG, Torshin IYu, Grustlivaya UE, Prozorova NV, Egorova EYu et al. On the diagnosis of magnesium deficiency. Part 1. Russian Archive of Internal Medicine. 2014;(2):5–10. (In Russ.) Available at: https://www.medarhive.ru/jour/article/view/275.

9. Gragossian A, Bashir K, Bhutta BS, Friede R. Hypomagnesemia. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023. Available at: https://www.ncbi.nlm.nih.gov/books/NBK500003/.

10. Assarzadegan F, Asgarzadeh S, Hatamabadi HR, Shahrami A, Tabatabaey A, Asgarzadeh M. Serum concentration of magnesium as an independent risk factor in migraine attacks: a matched casecontrol study and review of the literature. Int Clin Psychopharmacol. 2016;31(5):287–292. https://doi.org/10.1097/YIC.0000000000000130.

11. Yaşin S, Altunışık E. Decreased serum magnesium levels patients with migraine: a case control study. IAMR. 2023;15(1):26–32. https://doi.org/10.56484/iamr.1217558.

12. Cegielska J, SzmidtSalkowska E, Domitrz W, Gawel M, RadziwonZaleska M, Domitrz I. Migraine and Its Association with Hyperactivity of Cell Membranes in the Course of Latent Magnesium DeficiencyPreliminary Study of the Importance of the Latent Tetany Presence in the Migraine Pathogenesis. Nutrients. 2021;13(8):2701. https://doi.org/10.3390/nu13082701.

13. Thomas J, Millot JM, Sebille S, Delabroise AM, Thomas E, Manfait M, Arnaud MJ. Free and total magnesium in lym phocytes of migraine patients – effect of magnesiumrich mineral water intake. Clin Chim Acta. 2000;295(12):63–75. https://doi.org/10.1016/s00098981(00)001868.

14. Gromova OA, Torshin IIu, Kalacheva AG, Kuramshina DB. Molecularbiological basics of neuroprotection effects of magnesium. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2011;111(12):90–101. (In Russ.) Available at: https://www.mediasphera.ru/issues/zhurnalnevrologiii-psikhiatriiims-skorsakova/2011/12/031997729820111218.

15. Hansen KB, Yi F, Perszyk RE, Menniti FS, Traynelis SF. NMDA Receptors in the Central Nervous System. Methods Mol Biol. 2017;1677:1–80. https://doi.org/10.1007/9781-493973217_1.

16. Hansen KB, Yi F, Perszyk RE, Furukawa H, Wollmuth LP, Gibb AJ, Traynelis SF. Structure, function, and allosteric modulation of NMDA receptors. J Gen Physiol. 2018;150(8):1081–1105. https://doi.org/10.1085/jgp.201812032.

17. Kukushkin ML. Mechanisms of chronic pain development. Approaches to prevention and treatment. Consilium Medicum. 2017;19(2):110 –117. (In Russ.) Available at: https://consilium.orscience.ru/20751753/article/view/94745/pdf.

18. Pockett, S. Spinal cord synaptic plasticity and chronic pain. Anesth Analg. 1995;80(1):173–179. https://doi.org/10.1097/0000053919950100000026.

19. Latremoliere A, Woolf CJ. Central sensitization: a generator of pain hypersensitivity by central neural plasticity. J Pain. 2009;10(9):895–926. https://doi.org/10.1016/j.jpain.2009.06.012.

20. Woolf CJ, Thompson SWN. The induction and maintenance of central sensitization is dependent on NmethylD-aspartic acid receptor activation; implications for the treatment of postinjury pain hypersensitivity states. Pain. 1991;44(3):293–299. https://doi.org/10.1016/03043959(91)90100C.

21. Mayer ML, Westbrook GL, Guthrie PB. Voltagedependent block by Mg2+ of NMDA responses in spinal cord neurones. Nature. 1984;309(5965):261–263. https://doi.org/10.1038309261a0.

22. Амелин АВ, Игнатов ЮД, Скоромец АА, Соколов АЮ. Мигрень (патогенез, клиника, лечение). М.: МЕДпресс; 2011; 265 с

23. Mantegazza M, Cestèle S. Pathophysiological mechanisms of migraine and epilepsy: Similarities and differences. Neurosci Lett. 2018;667:92–102. https://doi.org/10.1016/j.neulet.2017.11.025.

24. Maier JA, Pickering G, Giacomoni E, Cazzaniga A, Pellegrino P. Headaches and Magnesium: Mechanisms, Bioavailability, Therapeutic Efficacy and Potential Advantage of Magnesium Pidolate. Nutrients. 2020;12(9):2660. https://doi.org/10.3390/nu12092660.

25. Romanenko AV, Murzo VV, Popovskaya KA, Seliverstova EG, Gorbachev NA, Turgunkhujaev OE. Calcitonin generelated peptide in pathophysiology of migraine. Russian Journal of Pain. 2024;22(2):56–67. (In Russ.) https://doi.org/10.17116/pain20242202156.

26. Weglicki WB, Mak IT, Phillips TM. Blockade of cardiac inflammation in Mg2+ deficiency by substance P receptor inhibition. Circ Res. 1994;74(5):1009–1013. https://doi.org/10.1161/01.res.74.5.1009.

27. Bareyre FM, Saatman KE, Raghupathi R, McIntosh TK. Postinjury treatment with magnesium chloride attenuates cortical damage after traumatic brain injury in rats. J Neurotrauma. 2000;17(11):1029–1039. https://doi.org/10.1089/neu.2000.17.1029.

28. Bareyre FM, Saatman KE, Helfaer MA, Sinson G, Weisser JD, Brown AL, McIntosh TK. Alterations in ionized and total blood magnesium after experimental traumatic brain injury: relationship to neurobehavioral outcome and neuroprotective efficacy of magnesium chloride. J Neurochem. 1999;73(1):271–280. https://doi.org/10.1046/j.14714159.1999.0730271.x.

29. Hoane MR. Assessment of cognitive function following magnesium therapy in the traumatically injured brain. Magnes Res. 2007;20(4):229–236. Available at: https://www.jle.com/fr/revues/mrh/e-docs/assessment_of_cognitive_function_following_magnesium_therapy_in_the_traumatically_injured_brain_276440/article.phtml.

30. Hoane MR, Gilbert DR, Barbre AB, Harrison SA. Magnesium dietary manipulation and recovery of function following controlled cortical damage in the rat. Magnes Res. 2008;21(1):29–37. Available at: https://www.jle.com/fr/revues/mrh/e-docs/magnesium_dietary_manipulation_and_recovery_of_function_following_controlled_cortical_damage_in_the_rat_277376/article.phtml.

31. Cernak I, Savic VJ, Kotur J, Prokic V, Veljovic M, Grbovic D. Characterization of plasma magnesium concentration and oxidative stress following graded traumatic brain injury in humans. J Neurotrauma. 2000;17(1):53–68. https://doi.org/10.1089/neu.2000.17.53.

32. Sen AP, Gulati A. Use of magnesium in traumatic brain injury. Neurotherapeutics. 2010;7(1):91–99. Available at: https://link.springer.com/article/10.1016/j.nurt.2009.10.014.

33. Myrdal U, Leppert J, Edvinsson L, Ekman R, Hedner T, Nilsson H, Ringqvist I. Magnesium sulphate infusion decreases circulating calcitonin gene-r elated peptide (CGRP) in women with primary Raynaud’s phenomenon. Clin Physiol. 1994;14(5):539–546. https://doi.org/10.1111/j.1475097x.1994.tb00412.x.

34. Mauskop A, Altura BT, Cracco RQ, Altura BM. Intravenous magnesium sulphate relieves migraine attacks in patients with low serum ionized magnesium levels: A pilot study. Clin Sci. 1995;89(6):633–636. https://doi.org/10.1042/cs0890633.

35. Demirkaya S, Vural O, Dora B, Topçuoğlu MA.Efficacy of intravenous magnesium sulfate in the treatment of acute mi graine attacks. Headache. 2001;41(2):171–177. https://doi.org/10.1046/j.1526-4610.2001.111006171.x.

36. von Luckner A, Riederer F. Magnesium in Migraine Prophylaxis-I s There an EvidenceBased Rationale? A Systematic Review. Headache. 2018;58(2):199–209. https://doi.org/10.1111/head.13217.

37. Köseoglu E, Talaslioglu A, Gönül AS, Kula M. The effects of magnesium prophylaxis in migraine without aura. Magnes Res. 2008;21(2):101–108. Available at: https://www.jle.com/fr/revues/mrh/e-docs/the_effects_of_magnesium_prophylaxis_in_migraine_without_aura_278046/article.phtml.

38. Khani S, Hejazi SA, Yaghoubi M, Sharifipour E. Comparative study of magnesium, sodium valproate, and concurrent magnesiumsodium valproate therapy in the prevention of migraine headaches: a randomized controlled doubleblind trial. J Headache Pain. 2021;22(1):21. https://doi.org/10.1186/s10194021012346.

39. Pardo MR, Garicano Vilar E, San Mauro Martín I, Camina Martín MA. Bioavailability of magnesium food supplements: A systematic review. Nutrition. 2021;89:111294. https://doi.org/10.1016/j.nut.2021.111294.

40. Ates M, Kizildag S, Yuksel O, Hosgorler F, Yuce Z, Guvendi G et al. Dose-D ependent Absorption Profile of Different Magnesium Compounds. Biol Trace Elem Res. 2019;192(2):244–251. https://doi.org/10.1007/s12011019016630.

41. Schuette SA, Lashner BA, Janghorbani M. Bioavailability of magnesium diglycinate vs magnesium oxide in patients with ileal resection. JPEN J Parenter Enteral Nutr. 1994;18(5):430–435. https://doi.org/10.1177/0148607194018005430.

42. Schiopu C, Ștefănescu G, Diaconescu S, Bălan GG, Gimiga N, Rusu E et al. Magnesium Orotate and the Microbiome-Gut-Brain Axis Modulation: New Approaches in Psychological Comorbidities of Gastrointestinal Functional Disorders. Nutrients. 2022;14(8):1567. https://doi.org/10.3390/nu14081567.

43. Romeo V, Cazzaniga A, Maier JAM. Magnesium and the bloodbrain barrier in vitro: Effects on permeability and magnesium transport. Magnes Res. 2019;32(1):16–24. Available at: https://www.jle.com/en/revues/mrh/e-docs/magnesium_and_the_blood_brain_barrier_in_vitro_effects_on_permeability_and_magnesium_transport_315186/article.phtml.

44. Noah L, Dye L, Bois De Fer B, Mazur A, Pickering G, Pouteau E. Effect of magnesium and vitamin B6 supplementation on mental health and quality of life in stressed healthy adults: Posthoc analysis of a randomised controlled trial. Stress Health. 2021;37(5):1000–1009. https://doi.org/10.1002/smi.3051.

45. Pouteau E, KabirAhmadi M, Noah L, Mazur A, Dye L, Hellhammer J et al. Superiority of magnesium and vitamin B6 over magnesium alone on severe stress in healthy adults with low magnesemia: A randomized, single-b lind clinical trial. PLoS ONE. 2018;13(12):e0208454. https://doi.org/10.1371/journal.pone.0208454.

46. Chiu HY, Yeh TH, Huang YC, Chen PY. Effects of Intravenous and Oral Magnesium on Reducing Migraine: A Metaanalysis of Randomized Controlled Trials. Pain Physician. 2016;19(1):E97–112. Available at: https://www.painphysicianjournal.com/linkout?issn=&vol=19&page=E97.

47. Азимова ЮЭ, Алферова ВВ, Амелин АВ, Артеменко АР, Ахмадеева ЛР, Головачева ВА и др. Мигрень: клинические рекомендации. М.; 2024. 92 с. Режим доступа: https://cr.minzdrav.gov.ru/previewcr/295_4.

48. Negro A, Delaruelle Z, Ivanova TA, Khan S, Ornello R, Raffaelli B et al. Headache and pregnancy: a systematic review. J Headache Pain. 2017;18(1):106. https://doi.org/10.1186/s1019401708160.